ClinicalTrials.gg
CompletedNCT04665050Updated Oct 4, 2023Results posted

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

A Phase 1 interventional study of V116 and PNEUMOVAX™23 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
10th of 10
102 · median 1,075
Started
2021
the only one that year
Phase 1
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 10th largest by enrollment, is the only one that started in 2021, is the only one in phase 1, and was the 1st registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety, tolerability, and immunogenicity of a polyvalent pneumococcal conjugate vaccine (V116) with that of PNEUMOVAX™23 in healthy Japanese adults.

03

Conditions studied

  • Pneumococcal Infection
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is a healthy Japanese male or female ≥20 years of age at time of randomization
  • male participants must agree to be abstinent or use during the intervention period and for ≥30 days after the last dose of study intervention
  • female participants must not be pregnant or breastfeeding, and is either:
  • not a woman of (WOCBP) or
  • a WOCBP who agrees to remain abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1
  • has a known to any vaccine components
  • has impaired immunological function
  • has a coagulation disorder
  • had a recent febrile illness (axillary temperature ≥37.5°C or equivalent) within 72 hours before Day 1
  • has a known that is progressing/requiring treatment
  • has received, or is expected to receive, a pneumococcal vaccine outside the study protocol
  • has received systemic (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed the regimen for ≥30 days prior to Day 1
  • is receiving therapy
  • has received any non- from 14 days prior to Day 1 other than inactivated influenza vaccine
  • has received any live vaccine from 30 days prior to Day 1
  • has received a blood transfusion or blood products
  • has participated in another clinical trial within 2 months of this study
  • has drug or alcohol abuse
  • has any condition that, in the opinion of the investigator, precludes participation in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    V116

    Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.

    Biological: V116

  • Active comparator
    PNEUMOVAX™23

    Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.

    Biological: PNEUMOVAX™23

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Polyvalent pneumococcal conjugate vaccine (pPCV), Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPNEUMOVAX™23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PPSV23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Solicited Injection-site Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.

    Time frame: Up to 5 days postvaccination

  2. Percentage of Participants With a Solicited Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.

    Time frame: Up to 5 days postvaccination

  3. Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)

    An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.

    Time frame: Up to 62 days postvaccination

Secondary outcomes

  1. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23

    The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group measures of dispersion (MOD) were not calculated.

    Time frame: Day 30 postvaccination

  2. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23

    The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

    Time frame: Day 30 postvaccination

  3. Serotype-specific OPA GMTs for the Unique Serotypes in V116

    The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

    Time frame: Day 30 postvaccination

  4. Serotype-specific IgG GMCs for the Unique Serotypes in V116

    The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

    Time frame: Day 30 postvaccination

  5. Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

    GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  6. GMFR From Baseline in Serotype-specific IgG GMCs

    GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

07

Results

Posted Jul 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneV116PNEUMOVAX™23
Started5151
Completed5151
Not completed00

Outcome measures

PrimaryPercentage of Participants With a Solicited Injection-site Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
Percentage of ParticipantsV116PNEUMOVAX™23
Injection site erythema9.89.8
Injection site pain54.966.7
Injection site swelling13.713.7
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 0.0 · 95% CI -12.7 to 12.7V116 minus PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Difference in percentage: -11.8 · 95% CI -30.0 to 7.3V116 minus PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 0.0 · 95% CI -14.1 to 14.1V116 minus PNEUMOVAX™23
PrimaryPercentage of Participants With a Solicited Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With a Solicited Systemic AE
Percentage of participantsV116PNEUMOVAX™23
Fatigue13.79.8
Arthralgia3.93.9
Myalgia17.619.6
Headache9.89.8
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 3.9 · 95% CI -9.4 to 17.5V116 minus PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 0.0 · 95% CI -9.9 to 9.9V116 minus PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Difference in percentage: -2.0 · 95% CI -17.5 to 13.6V116 minus PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 0.0 · 95% CI -12.7 to 12.7V116 minus PNEUMOVAX™23
PrimaryPercentage of Participants With a Vaccine-related Serious Adverse Event (SAE)

An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.

Time frame:
Up to 62 days postvaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)
Percentage of participantsV116PNEUMOVAX™23
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)0.00.0
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Difference in percentage: 0.0 · 95% CI -7.1 to 7.1V116 minus PNEUMOVAX™23
SecondarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23

The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group measures of dispersion (MOD) were not calculated.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · Titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23
TitersV116PNEUMOVAX™23
Serotype 3161.08 (NA to NA)100.76 (NA to NA)
Serotype 7F5327.67 (NA to NA)4406.11 (NA to NA)
Serotype 19A1479.82 (NA to NA)738.52 (NA to NA)
Serotype 22F5768.79 (NA to NA)3000.50 (NA to NA)
Serotype 33F33187.25 (NA to NA)28831.77 (NA to NA)
Serotype 81287.66 (NA to NA)721.85 (NA to NA)
Serotype 9N6555.82 (NA to NA)3466.72 (NA to NA)
Serotype 10A3608.34 (NA to NA)1330.75 (NA to NA)
Serotype 11A1467.66 (NA to NA)603.00 (NA to NA)
Serotype 12F1356.20 (NA to NA)563.99 (NA to NA)
Serotype 17F8470.21 (NA to NA)3293.31 (NA to NA)
Serotype 20A3542.90 (NA to NA)1553.99 (NA to NA)
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.60 · 95% CI 1.07 to 2.40V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.21 · 95% CI 0.69 to 2.11V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.00 · 95% CI 1.24 to 3.24V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.92 · 95% CI 1.04 to 3.57V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.15 · 95% CI 0.71 to 1.86V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.78 · 95% CI 1.24 to 2.58V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 1.89 · 95% CI 1.19 to 3.00V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.71 · 95% CI 1.47 to 5.00V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.43 · 95% CI 1.52 to 3.89V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.40 · 95% CI 1.20 to 4.83V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.57 · 95% CI 1.59 to 4.17V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.28 · 95% CI 1.46 to 3.56V116/PNEUMOVAX™23
SecondarySerotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23

The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · μg/mL
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23
μg/mLV116PNEUMOVAX™23
Serotype 31.13 (NA to NA)0.73 (NA to NA)
Serotype 7F10.29 (NA to NA)4.66 (NA to NA)
Serotype 19A10.75 (NA to NA)4.97 (NA to NA)
Serotype 22F3.94 (NA to NA)1.69 (NA to NA)
Serotype 33F22.00 (NA to NA)14.48 (NA to NA)
Serotype 819.38 (NA to NA)10.33 (NA to NA)
Serotype 9N14.17 (NA to NA)5.99 (NA to NA)
Serotype 10A11.13 (NA to NA)5.16 (NA to NA)
Serotype 11A9.07 (NA to NA)4.71 (NA to NA)
Serotype 12F2.87 (NA to NA)0.82 (NA to NA)
Serotype 17F19.46 (NA to NA)6.77 (NA to NA)
Serotype 20A23.53 (NA to NA)11.46 (NA to NA)
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 1.54 · 95% CI 1.08 to 2.21V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.21 · 95% CI 1.36 to 3.60V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.16 · 95% CI 1.45 to 3.23V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.33 · 95% CI 1.36 to 3.99V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 1.52 · 95% CI 0.97 to 2.37V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 1.88 · 95% CI 1.32 to 2.68V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.37 · 95% CI 1.49 to 3.74V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.16 · 95% CI 1.28 to 3.65V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 1.92 · 95% CI 1.28 to 2.89V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 3.49 · 95% CI 1.94 to 6.27V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.88 · 95% CI 1.92 to 4.31V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 2.05 · 95% CI 1.30 to 3.25V116/PNEUMOVAX™23
SecondarySerotype-specific OPA GMTs for the Unique Serotypes in V116

The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · Titers
Serotype-specific OPA GMTs for the Unique Serotypes in V116
TitersV116PNEUMOVAX™23
Serotype 6A1663.20 (NA to NA)464.65 (NA to NA)
Serotype 15A5030.66 (NA to NA)807.16 (NA to NA)
Serotype 15C3641.84 (NA to NA)1565.56 (NA to NA)
Serotype 16F2459.26 (NA to NA)244.49 (NA to NA)
Serotype 23A2620.19 (NA to NA)62.26 (NA to NA)
Serotype 23B2065.39 (NA to NA)167.03 (NA to NA)
Serotype 24F2742.93 (NA to NA)110.53 (NA to NA)
Serotype 311699.54 (NA to NA)66.24 (NA to NA)
Serotype 35B4992.58 (NA to NA)349.07 (NA to NA)
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 3.58 · 95% CI 1.86 to 6.88V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 6.23 · 95% CI 3.54 to 10.98V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 2.33 · 95% CI 1.23 to 4.39V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 10.06 · 95% CI 5.39 to 18.78V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 42.09 · 95% CI 19.67 to 90.03V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 12.37 · 95% CI 6.97 to 21.94V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 24.82 · 95% CI 11.65 to 52.86V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 25.66 · 95% CI 14.65 to 44.93V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmt ratio: 14.30 · 95% CI 8.72 to 23.47V116/PNEUMOVAX™23
SecondarySerotype-specific IgG GMCs for the Unique Serotypes in V116

The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · μg/mL
Serotype-specific IgG GMCs for the Unique Serotypes in V116
μg/mLV116PNEUMOVAX™23
Serotype 6A6.38 (NA to NA)2.13 (NA to NA)
Serotype 15A16.39 (NA to NA)2.04 (NA to NA)
Serotype 15C21.42 (NA to NA)6.81 (NA to NA)
Serotype 16F5.57 (NA to NA)0.43 (NA to NA)
Serotype 23A4.14 (NA to NA)0.48 (NA to NA)
Serotype 23B8.56 (NA to NA)2.06 (NA to NA)
Serotype 24F13.99 (NA to NA)0.49 (NA to NA)
Serotype 315.25 (NA to NA)0.51 (NA to NA)
Serotype 35B24.61 (NA to NA)1.54 (NA to NA)
Statistical analysis
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 3.00 · 95% CI 1.73 to 5.19V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 8.03 · 95% CI 4.61 to 13.98V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 3.14 · 95% CI 1.77 to 5.58V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 13.06 · 95% CI 8.45 to 20.19V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 8.55 · 95% CI 5.19 to 14.09V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 4.15 · 95% CI 2.72 to 6.36V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 28.68 · 95% CI 16.59 to 49.58V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 10.27 · 95% CI 6.71 to 15.73V116/PNEUMOVAX™23
  • V116 vs PNEUMOVAX™23 · Gmc ratio: 15.95 · 95% CI 11.62 to 21.90V116/PNEUMOVAX™23
SecondaryGeometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
RatioV116PNEUMOVAX™23
Serotype 39.86 (7.07 to 13.75)6.35 (4.43 to 9.10)
Serotype 7F19.79 (10.60 to 36.94)21.53 (11.79 to 39.30)
Serotype 19A10.80 (7.27 to 16.04)6.74 (4.45 to 10.18)
Serotype 22F15.14 (8.25 to 27.79)18.13 (9.17 to 35.85)
Serotype 33F11.47 (8.20 to 16.04)11.62 (7.91 to 17.06)
Serotype 8102.33 (75.07 to 139.50)48.14 (32.69 to 70.88)
Serotype 9N55.49 (31.26 to 98.50)40.11 (22.97 to 70.03)
Serotype 10A31.29 (15.34 to 63.81)21.93 (12.29 to 39.11)
Serotype 11A42.06 (25.15 to 70.32)20.68 (12.11 to 35.33)
Serotype 12F94.74 (54.15 to 165.76)44.70 (24.59 to 81.24)
Serotype 17F23.63 (13.40 to 41.68)11.40 (7.07 to 18.40)
Serotype 20A11.69 (7.27 to 18.81)5.94 (4.12 to 8.57)
Serotype 6A22.76 (12.66 to 40.93)8.31 (5.24 to 13.17)
Serotype 15A10.70 (6.31 to 18.13)3.02 (1.67 to 5.43)
Serotype 15C36.53 (18.49 to 72.15)16.72 (9.39 to 29.76)
Serotype 16F14.74 (8.27 to 26.28)1.84 (1.10 to 3.06)
Serotype 23A46.69 (25.58 to 85.22)1.93 (1.05 to 3.56)
Serotype 23B43.21 (25.15 to 74.23)4.43 (3.00 to 6.54)
Serotype 24F9.21 (5.06 to 16.78)0.75 (0.40 to 1.40)
Serotype 3127.99 (16.04 to 48.85)1.22 (0.75 to 2.01)
Serotype 35B7.39 (4.32 to 12.67)0.56 (0.41 to 0.78)
Serotype 6C5.63 (3.17 to 9.99)4.00 (2.21 to 7.24)
Serotype 15B35.68 (18.43 to 69.08)23.54 (13.35 to 41.50)
Serotype 20B6.08 (3.16 to 11.71)8.89 (5.29 to 14.95)
SecondaryGMFR From Baseline in Serotype-specific IgG GMCs

GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
GMFR From Baseline in Serotype-specific IgG GMCs
RatioV116PNEUMOVAX™23
Serotype 35.92 (4.25 to 8.24)4.47 (3.48 to 5.74)
Serotype 7F23.86 (16.20 to 35.14)10.51 (7.57 to 14.58)
Serotype 19A7.58 (5.51 to 10.44)3.52 (2.71 to 4.56)
Serotype 22F14.68 (9.24 to 23.30)6.57 (4.65 to 9.28)
Serotype 33F21.61 (14.49 to 32.23)11.52 (8.24 to 16.13)
Serotype 831.58 (22.46 to 44.39)16.71 (12.61 to 22.14)
Serotype 9N24.26 (16.60 to 35.46)10.56 (8.01 to 13.92)
Serotype 10A15.70 (10.45 to 23.59)7.19 (5.13 to 10.07)
Serotype 11A9.31 (6.51 to 13.31)4.64 (3.47 to 6.22)
Serotype 12F23.87 (15.22 to 37.44)6.53 (4.52 to 9.44)
Serotype 17F20.71 (15.14 to 28.33)7.37 (5.60 to 9.69)
Serotype 20A11.68 (8.14 to 16.77)6.19 (4.57 to 8.38)
Serotype 6A14.01 (8.99 to 21.86)4.67 (3.28 to 6.63)
Serotype 15A32.11 (18.79 to 54.89)3.34 (2.52 to 4.44)
Serotype 15C42.20 (25.71 to 69.25)11.50 (7.83 to 16.88)
Serotype 16F21.00 (14.13 to 31.23)1.52 (1.33 to 1.73)
Serotype 23A18.42 (12.28 to 27.63)2.26 (1.67 to 3.06)
Serotype 23B14.04 (9.14 to 21.58)3.22 (2.55 to 4.06)
Serotype 24F31.58 (18.26 to 54.60)1.15 (1.01 to 1.31)
Serotype 3117.97 (12.37 to 26.10)1.64 (1.28 to 2.09)
Serotype 35B16.93 (11.99 to 23.90)1.10 (1.05 to 1.15)
Serotype 6C5.94 (4.25 to 8.30)2.21 (1.79 to 2.74)
Serotype 15B11.14 (7.39 to 16.78)8.61 (6.14 to 12.08)

Adverse events

Collected over Up to 62 days postvaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V1160/51 (0%)0/51 (0%)30/51 (58.8%)
PNEUMOVAX™230/51 (0%)0/51 (0%)35/51 (68.6%)
Most frequent other events
Most frequent other events
EventV116PNEUMOVAX™23
Injection site painGeneral disorders28/5134/51
MyalgiaMusculoskeletal and connective tissue disorders9/5110/51
FatigueGeneral disorders7/515/51
Injection site swellingGeneral disorders7/517/51
Injection site erythemaGeneral disorders5/515/51
HeadacheNervous system disorders5/515/51
PyrexiaGeneral disorders0/513/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V116PNEUMOVAX™23Total
Mean63.1 ± 13.764.0 ± 12.763.6 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)V116PNEUMOVAX™23Total
Female282452
Male232750
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V116PNEUMOVAX™23Total
Hispanic or Latino000
Not Hispanic or Latino5151102
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V116PNEUMOVAX™23Total
American Indian or Alaska Native000
Asian5151102
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Souseikai PS Clinic ( Site 0201)
    Fukuoka, 812-0025, Japan
  • Souseikai Nishikumamoto Hospital ( Site 0202)
    Kumamoto, 861-4157, Japan
09

References and documents

Publications

  • Haranaka M, Yono M, Kishino H, Igarashi R, Oshima N, Sawata M, Platt HL. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228162. doi: 10.1080/21645515.2023.2228162. PubMed 37389808 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2021, 2 months.

Results were first posted in Jul 2023, 2 years 3 months after primary completion.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 11, 2020
StartActual
Feb 4, 2021
Primary completionActual
Apr 6, 2021
CompletionActual
Apr 6, 2021
Results first posted
Jul 7, 2023
Last update
Oct 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04665050
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Feb 4, 2021
Primary completion
Apr 6, 2021
Completion
Apr 6, 2021
Results posted
Jul 7, 2023
Last update
Oct 4, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion